Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Sandostatin LAR Octreotide acetate 11.2mg equivalent to Octreotide 10mg Powder for injection with diluent Novartis New Zealand Limited Sandoz GmbH, Tyrol, Austria
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Sandostatin LAR Octreotide acetate 22.4mg equivalent to Octreotide 20mg Powder for injection with diluent Novartis New Zealand Limited Sandoz GmbH, Tyrol, Austria
|
Product: Active Ingredient: Dosage Form: New Zealand Sponsor: Manufacturer:
|
Sandostatin LAR Octreotide acetate 33.6mg equivalent to Octreotide 30mg Powder for injection with diluent Novartis New Zealand Limited Sandoz GmbH, Tyrol, Austria
|
Dated this 29th day of May 2015.
CHRIS JAMES, Acting Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).